Clinical trial
A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
NCT00214500 · Amicus Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00214500 |
|---|---|
| Title | A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease |
| Official title | A Phase 2, Open-Label, Multicenter, 12-Week Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AT1001 in Patients With Fabry Disease |
| Lead sponsor | Amicus Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fabry Disease |
| Intervention type | Drug |
| Interventions | migalastat HCl |
| Enrollment | 9 |
| Start date | Jan 2, 2006 |
| Primary completion | Jan 29, 2008 |
| Completion | Jan 29, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | Oct 30, 2018 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: